Press Releases

RetinalGeniX™ Technologies Inc. Contracts with Medsan, Inc. to Provide Diagnostic Testing Services for its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration

PETALUMA, Calif., December 26, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has contracted with MEDsan, Inc. (“MEDsan” to provide diagnostic testing services for its Institutional Review Board (IRB) to conduct a study to personalize medical evaluations for patients receiving treatment for

Read More »
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board

PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) — RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D. has joined the Company’s Medical Advisory Board. RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and

Read More »
RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors

PETALUMA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) — RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Dessislava (Dessy) Boneva, M.D. has joined the Company’s Board of Directors. RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging

Read More »
RetinalGeniX Technologies Inc. Appoints Stephen Tannenbaum to the Company’s Business Advisory Board

PETALUMA, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Stephen Tannenbaum to the Business Advisory Board of RetinalGeniX. Mr. Tannenbaum will provide strategic business advice, consult on potential mergers and acquisitions, and the development of channels to acquire

Read More »
RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs

PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024. RTG-2023 is being developed to treat dry age-related macular degeneration (AMD).

Read More »
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device

PETALUMA, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has contracted with Avania CRO to provide guidance for the Company’s interactions with the FDA for the development of [1] RTG-2023 for the treatment of dry age-related macular degeneration (dry

Read More »
RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration

PETALUMA, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced the launch of an Institutional Review Board (“IRB”) for research on its DNA/GPS program. The study aims to offer recommendations for enhancing the preselection process and management of ocular injections. The proposed

Read More »
RetinalGeniX Technologies Inc. Focuses on Prevention of Blindness and Early Detection of Multiple Systemic Diseases

PETALUMA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) — RetinalGeniX Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) released to the public via OTC Markets, a video webinar regarding the retinal screening medical device technology being developed by the Company to help prevent blindness and multiple systemic diseases, the Company’s business opportunities and the professional background

Read More »
RetinalGeniX Technologies Inc. Granted Patent for Patient Home Monitoring and Physician Alert System for Ocular Anatomy

PETALUMA, Calif., July 28, 2023 (GLOBE NEWSWIRE) — Technology Enables Physicians to Remotely Make Pre-Diagnostic Assessment Regarding Whether an In-Person Diagnostic Examination of Ocular Anatomy is Warranted. RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), this week was granted a patent for its Patient Home Monitoring and Integrated Physician Alert System

Read More »
RetinalGeniX Technologies, Inc. Nears Completion of Institutional Review Board for Research on DNA/GPS Program

PETALUMA, Calif., June 26, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today previewed the completion of an Institutional Review Board (“IRB”) for research on its DNA/GPS program. The study aims to offer recommendations for enhancing the management of ocular injections, which have become a significant

Read More »
Retinalgenix Technologies, Inc. Expands Team to Hasten the Launch of DNA/GPS

PETALUMA, Calif., June 07, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), announced today the hiring of Owen Watson, MS. Watson Hired to Accelerate DNA-Based “GPS” Genetic Testing App Which Combines with RTGN’s High-Resolution Retinal Imaging Technologies Seeking to Revolutionize Diagnosis of Systemic Diseases. Mr. Watson’s

Read More »
RetinalGeniX Technologies, Inc. Acquires DNA/GPS Inc.

PETALUMA, Calif., July 06, 2022 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), announced today the acquisition of DNA/GPS Inc., a pharmacogenetics company based in Tampa, Florida and founded by Dr. Larry Perich. RetinalGeniX now has the rights to the platform technology designed by Dr. Perich, which allows healthcare providers

Read More »
RetinalGeniX™ Technologies Selects OPTIONTRAX for Equity Management

PETALUMA, Calif., Oct. 21, 2020 /PRNewswire/ — RetinalGeniX™ Technologies, Inc. https://retinalgenix.com/ announced today that it has awarded a contract to Plan Management Corporation (PMC) for use of their OPTIONTRAX Equity Plan and Cap Table Software. RetinalGeniX™ Technologies is a private California-based medical technology company focused on prevention of blindness through mass medical

Read More »
ADM Tronics to Develop Patented, Next-Generation Ophthalmic Diagnostic System for RetinalGeniX Technologies, Inc.

January 13, 2020    Northvale, NJ, Jan. 13, 2020 (GLOBE NEWSWIRE) — ADM Tronics Unlimited, Inc. (OTCQB: ADMT) announced that RetinalGeniX Technologies, Inc. (“RTI”), has entered into an engineering development agreement for ADMT to develop and manufacture RTI’s patented, next-generation ophthalmic diagnostic technology known as the RetinalGeniX™ system.  The RetinalGeniX system is

Read More »